The mAb806 antibody has been tested in clinical trials for EGFR-overexpressing tumors, and showed specific binding to tumor tissue, including malignant glioma, with only mild gastrointestinal and dermatologic side effects [24]. This evidence concerns the gene EGFR and neoplasm.